OBJECTIVES: To estimate prevalence and determinants of high risk (HR) human papillomavirus (HPV) by country of origin in women attending a family planning centre (FPC) in Alicante, Spain. METHODS: Cross sectional study of all women attending a FPC from May 2003 to January 2004. An ad hoc questionnaire was designed and data were collected prospectively. HR HPV infection was determined through the Digene HPV test, Hybrid Capture II, and positive samples for PCR were directly sequenced. Data were analysed through multiple logistic regression. RESULTS: HR HPV prevalence in 1011 women was 10% (95% CI: 8.2 to 12). Compared to Spaniards (prevalence 8.2%) HR HPV prevalence in Colombians was 27.5% (OR: 4.24 95% CI: 2.03 to 8.86), 23.1% in Ecuadoreans (OR: 3.35 95% CI: 1.30 to 8.63), and 22.73% in women from other Latin American countries (OR: 3.29 95% CI: 1.17 to 9.19). Women with more than three lifetime sexual partners had an increased risk of HR HPV infection (OR 3.21 95% CI: 2.02 to 5.10). The higher risk of HR HPV infection was maintained in Latin American women in multivariate analyses that adjusted for age, number of lifetime sexual partners, and reason for consultation. The commonest HPV types in women with normal cervical smears were HPV-18 (20%), HPV-16 (14%) and HPV-33 (11%). CONCLUSIONS: Prevalence of HR HPV is more than three times higher in Latin Americans than in Spaniards. Latin American women's HPV prevalence resembles more that of their countries of origin. It is essential that health service providers identify these women as a priority group in current cervical screening programmes.
OBJECTIVES: To estimate prevalence and determinants of high risk (HR) human papillomavirus (HPV) by country of origin in women attending a family planning centre (FPC) in Alicante, Spain. METHODS: Cross sectional study of all women attending a FPC from May 2003 to January 2004. An ad hoc questionnaire was designed and data were collected prospectively. HR HPV infection was determined through the Digene HPV test, Hybrid Capture II, and positive samples for PCR were directly sequenced. Data were analysed through multiple logistic regression. RESULTS:HR HPV prevalence in 1011 women was 10% (95% CI: 8.2 to 12). Compared to Spaniards (prevalence 8.2%) HR HPV prevalence in Colombians was 27.5% (OR: 4.24 95% CI: 2.03 to 8.86), 23.1% in Ecuadoreans (OR: 3.35 95% CI: 1.30 to 8.63), and 22.73% in women from other Latin American countries (OR: 3.29 95% CI: 1.17 to 9.19). Women with more than three lifetime sexual partners had an increased risk of HR HPV infection (OR 3.21 95% CI: 2.02 to 5.10). The higher risk of HR HPV infection was maintained in Latin American women in multivariate analyses that adjusted for age, number of lifetime sexual partners, and reason for consultation. The commonest HPV types in women with normal cervical smears were HPV-18 (20%), HPV-16 (14%) and HPV-33 (11%). CONCLUSIONS: Prevalence of HR HPV is more than three times higher in Latin Americans than in Spaniards. Latin American women's HPV prevalence resembles more that of their countries of origin. It is essential that health service providers identify these women as a priority group in current cervical screening programmes.
Authors: Catterina Ferreccio; Rodrigo B Prado; Amaranta V Luzoro; Sandra Ll Ampuero; Peter J F Snijders; Chris J L M Meijer; Salvatore V Vaccarella; Alejandro T Jara; Klaus I Puschel; Sylvia C Robles; Rolando Herrero; Silvia F Franceschi; Jose M Ojeda Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: A Touzé; S de Sanjosé; P Coursaget; M R Almirall; V Palacio; C J Meijer; J Kornegay; F X Bosch Journal: J Clin Microbiol Date: 2001-12 Impact factor: 5.948
Authors: J del Amo; C González; J Losana; P Clavo; L Muñoz; J Ballesteros; A García-Saiz; M J Belza; M Ortiz; B Menéndez; J del Romero; F Bolumar Journal: Sex Transm Infect Date: 2005-02 Impact factor: 3.519
Authors: Trudee A Tarkowski; Emilia H Koumans; Mary Sawyer; Antonya Pierce; Carolyn M Black; John R Papp; Lauri Markowitz; Elizabeth R Unger Journal: J Infect Dis Date: 2003-12-22 Impact factor: 5.226
Authors: Thi Hoang Anh Pham; Trong Hieu Nguyen; Rolando Herrero; Salvatore Vaccarella; Jennifer S Smith; Thi Thuy Nguyen Thuy; Hoai Nga Nguyen; Ba Duc Nguyen; Rhoda Ashley; Peter J F Snijders; Chris J L M Meijer; Nubia Muñoz; D Max Parkin; Silvia Franceschi Journal: Int J Cancer Date: 2003-03-20 Impact factor: 7.396
Authors: Silvia de Sanjose; Rosa Almirall; Belen Lloveras; Rebeca Font; Mireia Diaz; Nubia Muñoz; Isabel Català; Chris J L M Meijer; Peter J F Snijders; Rolando Herrero; F Xavier Bosch Journal: Sex Transm Dis Date: 2003-10 Impact factor: 2.830
Authors: J O Thomas; R Herrero; A A Omigbodun; K Ojemakinde; I O Ajayi; A Fawole; O Oladepo; J S Smith; A Arslan; N Muñoz; P J F Snijders; C J L M Meijer; S Franceschi Journal: Br J Cancer Date: 2004-02-09 Impact factor: 7.640
Authors: M Molano; H Posso; E Weiderpass; A J C van den Brule; M Ronderos; S Franceschi; C J L M Meijer; A Arslan; N Munoz Journal: Br J Cancer Date: 2002-07-29 Impact factor: 7.640
Authors: M Ortiz; M Torres; L Muñoz; E Fernández-García; J Canals; A I Cabornero; E Aguilar; J Ballesteros; J Del Amo; A García-Sáiz Journal: J Clin Microbiol Date: 2006-04 Impact factor: 5.948
Authors: Esther Roura; Thomas Iftner; José Antonio Vidart; Susanne Krüger Kjaer; F Xavier Bosch; Nubia Muñoz; Santiago Palacios; Maria San Martin Rodriguez; Carmen Morillo; Laurence Serradell; Laurence Torcel-Pagnon; Javier Cortes; Xavier Castellsagué Journal: BMC Infect Dis Date: 2012-06-26 Impact factor: 3.090
Authors: Miguel Andujar; Esther Roura; Alejandra Torres; Begoña Vega; Marta Pavcovich; Miguel Angel Sanchez; Amina Lubrano; Jose Luis Trujillo; Lucia Almeida; Milagros Santana; Rosaura Hurtado; Octavio Arencibia; Virginia Benito; Norberto Medina; Sonia Carballo; Maria Del Carmen Camacho; Arancha Ruiz Del Pozo; Alfoso Quesada; Eduardo Salido; Silvia de Sanjosé; Laia Bruni Journal: BMJ Open Date: 2020-09-24 Impact factor: 2.692